Dr. Jeffrey H Lipton CML Chronic Myeloid Leukemia
"Jeff Lipton, PhD MD FRCPC is Professor of Medicine at the University of Toronto, Head of the CML Group and Director of the Allogeneic Blood and Marrow Transplant Service at the Princess Margaret Hospital. He received and honors BSc in Biochemistry at the University of Calgary and went on to a PhD in Biochemistry at the University of Western Ontario. After an MRC post-doctoral fellowship at the Weizmann Institute in Israel and junior staff at the University of Connecticut, he went back to Calgary to go to medical school, followed by a residency in Internal Medicine. He then completed sub-specialty training in Medical Oncology at the University of Toronto and stayed on at the PMH as a staff physician. His clinical practice is in chronic leukemias and bone marrow failure syndromes as well as allogeneic stem cell transplant. Research interests in particular are in CML and its therapy, outcomes and supportive care in BMT, and in the therapy of bone marrow failure syndromes. He has authored or co-authored more than 180 peer reviewed papers and 200 abstracts"
Extract of http://www.cbmtg.org/executive_board/.
VIDEOS
Understanding the cause of TKI resistance to improve management strategies in CML
July 2023, VJHemOnc – Video Journal of Hematology & HemOnc
Efficacy & tolerability of available TKI therapies in CML & managing TKI resistance
July 2023, VJHemOnc – Video Journal of Hematology & HemOnc
COVID Q&A with Dr. Jeff Lipton
June 2, 2020, The Canadian CML Network
Living Well with CML 2018: Q&A with Dr. Jeff Lipton
June 25, 2018, The Canadian CML Network
The practicalities of treating CML with generic therapies - Experience and recommendations
2016, iCMLf
How Should Chronic-phase CML Management be Influenced by RT-PCR Results at 3 Months+
May 15, 2015, ImedexCME
News from ASCO: Could Some Patients Stop Taking Medication for CML?
February 20, 2013, Patient Power
Living with chronic myeloid leukemia - Tasigna
August 2010, Info4YourLife
New leukemia treatment - Sprycel
2007, by Info4YourLife
Understanding the cause of TKI resistance to improve management strategies in CML
July 2023, VJHemOnc – Video Journal of Hematology & HemOnc
Efficacy & tolerability of available TKI therapies in CML & managing TKI resistance
July 2023, VJHemOnc – Video Journal of Hematology & HemOnc
COVID Q&A with Dr. Jeff Lipton
June 2, 2020, The Canadian CML Network
Living Well with CML 2018: Q&A with Dr. Jeff Lipton
June 25, 2018, The Canadian CML Network
The practicalities of treating CML with generic therapies - Experience and recommendations
2016, iCMLf
How Should Chronic-phase CML Management be Influenced by RT-PCR Results at 3 Months+
May 15, 2015, ImedexCME
News from ASCO: Could Some Patients Stop Taking Medication for CML?
February 20, 2013, Patient Power
Living with chronic myeloid leukemia - Tasigna
August 2010, Info4YourLife
New leukemia treatment - Sprycel
2007, by Info4YourLife